SAUDI ARABIA – EVA Pharma has officially hosted its groundbreaking ceremony for its new research and manufacturing complex in Sudair in the central region of the Kingdom of Saudi Arabia.
In partnership with MODON, EVA Pharma is investing in a state-of-the-art research and manufacturing complex situated in Sudair.
The plot attained, facilitated by MODON, will house a full-fledged industrial complex that will cater to a diverse spectrum of therapeutic domains with plans to launch over 150 pharmaceutical products.
In addition to the groundbreaking ceremony for the state-of-the-art complex in Sudair, EVA Pharma inaugurated its new office in the city of Riyadh.
In a news release, Riad Armanious, Chief Executive Officer of EVA Pharma, said: “As we break ground for this first-of-its-kind cluster in the Kingdom, we will maintain our momentum. We are gearing up to start production soon.”
Riad Armanious expressed his gratitude for the Saudi support while lauding both individuals and entities across the Kingdom that have helped and inspired EVA Pharma.
EVA Pharma is one of the fastest-growing pharmaceutical companies in the Middle East and Africa (MEA) region.
The pharmaceutical company manufactures more than one million packs of over 300 healthcare solutions on a daily basis at its three internationally accredited facilities.
Eva Pharma’s selection of Sudair for its full-fledged pharmaceutical industrial complex demonstrates its confidence in the investment climate in the Kingdom of Saudi Arabia.
With a research and development center at the heart of its industrial complex, EVA Pharma is preparing to scale its physical presence in the Kingdom of Saudi Arabia.
The industrial complex aims to become a center of gravity for pharmaceutical manufacturing in the region with sustainable accessibility for innovative healthcare solutions.
EVA Pharma affirmed its strategic partnership with the Ministry of Investment through the signing of a memorandum of understanding (MoU) as part of the groundbreaking ceremony for this complex.
In collaboration with MODON, EVA Pharma has selected IO, a German consultancy specializing in the implementation of complex industrial projects, to design and build its industrial complex.
The Sudair complex embodies a green circular economy approach as a component of EVA Pharma’s endeavors to reduce waste and enhance resource utilization via innovative technologies.
“This assembly of manufacturing facilities will bring cutting-edge technologies to Saudi Arabia so that the nation can reach the healthcare independence that it aspires to have,” stated Riad Armanious.
The Sudair complex, designed by German consultancy IO, not only pays homage to cultural roots but also strategically minimizes heat gain, thereby significantly reducing its carbon footprint.
Contributing to the overall reduction of environmental impact, the complex will incorporate solar panels, on-site water recycling, and waste treatment systems.
This demonstrates EVA Pharma’s environmentally conscious approach that aligns seamlessly with Saudi Arabia’s vision for a greener and more sustainable future.
To this end, the groundbreaking ceremony for the new research and manufacturing complex further solidifies EVA Pharma’s unwavering dedication to the Saudi market.
The industrial complex will comprise a research and development center (R&D) center and five pharmaceutical factories.
These five pharmaceutical factories include one for immunosuppressants and oncology products, another facility for biologics, a vaccines production unit, in addition to a facility for oral dosage forms.
Moreover, the industrial complex is projected to produce over 150 pharmaceutical products, which require specialized containment technology.
The pharmaceutical products span various therapeutic areas to help address the most demanding health challenges in the Kingdom.
“The company is ready to collaborate with Saudi industry stakeholders and we will bring cutting-edge technologies to meet unmet patients’ needs,” underscored Riad Armanious.
EVA Pharma’s strategic move into Saudi Arabia underscores its dedication to meeting unmet patient needs as the company marks its initial steps in the Saudi market through substantial local investments.
By establishing an industrial complex in Sudair, EVA Pharma is also well-suited to contribute to the Kingdom’s Vision 2030 healthcare goals of increasing the production of local pharmaceutical products.